SCHEMBL429754

SCHEMBL429754

Nc1c(C(=O)c2ccccc2)oc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 1.00
NPC1 O15118 9/20 1.00
KMT2A Q03164 3/20 1.00
SMN1; SMN2 Q16637 8/20 0.77
RAB9A P51151 7/20 0.77
AHR P35869 2/20 0.77
POLB P06746 1/20 0.77
KDM4E B2RXH2 5/20 0.71
TDP1 Q9NUW8 2/20 0.71
MEN1 O00255 2/20 0.71
ALDH1A1 P00352 2/20 0.71
HPGD P15428 1/20 0.71
CASP1 P29466 2/20 0.68
ADORA2A P29274 1/20 0.68
CYP1A2 P05177 1/20 0.63
CYP3A4 P08684 1/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63
PTPN1 P18031 2/20 0.60
TSHR P16473 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16794821 0.87 MAPT (0.77) MAPTNPC1KMT2ASMN1; SMN2RAB9A
SCHEMBL30979841 0.87 MAPT (1.00) MAPTNPC1KMT2ASMN1; SMN2RAB9A
SCHEMBL1869991 0.87 NPC1 (1.00) MAPTNPC1KMT2ASMN1; SMN2RAB9A
SCHEMBL9720114 0.87 MAPT (1.00) MAPTNPC1KMT2ASMN1; SMN2RAB9A
SCHEMBL30979845 0.87 MAPT (1.00) MAPTNPC1KMT2ASMN1; SMN2RAB9A
SCHEMBL2774740 0.84 MAPT (0.72) MAPTNPC1KMT2ASMN1; SMN2RAB9A
SCHEMBL16794816 0.84 MAPT (0.71) MAPTNPC1KMT2ASMN1; SMN2RAB9A
SCHEMBL6206238 0.84 SMN1; SMN2 (0.72) MAPTNPC1KMT2ASMN1; SMN2RAB9A
SCHEMBL16794802 0.84 NPC1 (0.72) MAPTNPC1KMT2ASMN1; SMN2RAB9A
SCHEMBL8805009 0.84 MAPT (1.00) MAPTNPC1KMT2ASMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230389344-A1 ORGANIC ELECTROLUMINESCENT DEVICE MERCK PATENT GMBH (DE) 2023-11-30 US disclosed
US-20230389344-A1 ORGANIC ELECTROLUMINESCENT DEVICE MERCK PATENT GMBH (DE) 2023-11-30 US disclosed
US-10957865-B2 Organic light emitting compound and organic light emitting diode including the same SFC CO., LTD. (KR) 2021-03-23 US disclosed
US-10957865-B2 Organic light emitting compound and organic light emitting diode including the same SFC CO., LTD. (KR) 2021-03-23 US disclosed
US-20210057655-A1 ORGANIC LIGHT EMITTING COMPOUND AND ORGANIC LIGHT EMITTING DIODE INCLUDING THE SAME SFC CO., LTD. (KR) 2021-02-25 US disclosed
US-20210057655-A1 ORGANIC LIGHT EMITTING COMPOUND AND ORGANIC LIGHT EMITTING DIODE INCLUDING THE SAME SFC CO., LTD. (KR) 2021-02-25 US disclosed
EP-3275970-B1 ORGANIC LIGHT EMITTING COMPOUND AND ORGANIC LIGHT EMITTING DIODE INCLUDING THE SAME SFC CO LTD (KR) 2019-05-22 EP disclosed
EP-3275970-B1 ORGANIC LIGHT EMITTING COMPOUND AND ORGANIC LIGHT EMITTING DIODE INCLUDING THE SAME SFC CO LTD (KR) 2019-05-22 EP disclosed
US-20180040834-A1 ORGANIC LIGHT EMITTING COMPOUND AND ORGANIC LIGHT EMITTING DIODE INCLUDING THE SAME SFC CO., LTD. (KR) 2018-02-08 US disclosed
US-20180040834-A1 ORGANIC LIGHT EMITTING COMPOUND AND ORGANIC LIGHT EMITTING DIODE INCLUDING THE SAME SFC CO., LTD. (KR) 2018-02-08 US disclosed
WO-2011054844-A1 CONDENSED AZEPINE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-05-12 WO disclosed
WO-2011054844-A1 CONDENSED AZEPINE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-05-12 WO disclosed
US-20110098483-A1 Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2011-04-28 US disclosed
US-20110098483-A1 Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2011-04-28 US disclosed
US-20110098483-A1 Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2011-04-28 US disclosed
WO-2009121033-A2 SUBSTITUTED NITROGEN HETEROCYCLES AND SYNTHESIS AND USES THEREOF UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-10-01 WO disclosed
WO-2009121033-A2 SUBSTITUTED NITROGEN HETEROCYCLES AND SYNTHESIS AND USES THEREOF UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-10-01 WO disclosed
US-20090247766-A1 Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-10-01 US disclosed
US-20090247766-A1 Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-10-01 US disclosed
US-20090247766-A1 Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180040834-A1 ORGANIC LIGHT EMITTING COMPOUND AND ORGANIC LIGHT EMITTING DIODE INCLUDING THE SAME HARS1, ALDH1A2, ALDH1A1 MAPT 2672/4885NPC1 121/4885KMT2A 2916/4885
US-20110098483-A1 Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof PAH, NAT1, NNT MAPT 3189/4885NPC1 123/4885KMT2A 2793/4885
US-20210057655-A1 ORGANIC LIGHT EMITTING COMPOUND AND ORGANIC LIGHT EMITTING DIODE INCLUDING THE SAME HARS1, ALDH1A2, ALDH1A1 MAPT 2672/4885NPC1 121/4885KMT2A 2916/4885
US-20090247766-A1 Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof PAH, NAT1, NNT MAPT 3189/4885NPC1 123/4885KMT2A 2793/4885
US-10957865-B2 Organic light emitting compound and organic light emitting diode including the same HARS1, ALDH1A2, ALDH1A1 MAPT 2735/4885NPC1 130/4885KMT2A 3006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.